Global ChronicKidney Disease Drugs Market, by Drug Type (ACE Inhibitors, B-blockers,Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents(ESAs), Phosphate Binders, and Others), by Route of Administration (Oral,Intravenous, and Subcutaneous), by Patient Type (Dialysis and Others), by DistributionChannel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and byRegion (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica), is estimated to be valued at US$ 12,328.2 million in 2020 and isexpected to exhibit a CAGR of 4.0% over the forecast period (2020-2027), ashighlighted in a new report published by Coherent Market Insights.
The increasing prevalence ofchronic kidney disease is expected to drive the market growth over the forecastperiod. For instance, according to the Centers for Disease Control andPrevention (CDC) estimations 2019, the chronic kidney disease is more common inpeople of age 65 years or above and around 125,000 people in the U.S. startedtreatment for end-stage kidney disease (ESKD) and over 726,000 (2 in every1,000 people) in 2018 were on dialysis or were living with a kidney transplant.
Chronic kidney disease is theprogressive loss of kidney function over a period of several years. As kidneyfailure advances to further stages, and the organ’s function is severelyimpaired, dangerous levels of waste and fluid can rapidly build up in the body.Early detection can help prevent the progression of kidney disease to kidneyfailure. Heart disease is the major cause of death for people with CKD.Treatment is aimed at stopping or slowing down the progression of the disease –this is usually done by controlling its underlying cause. ACE Inhibitors,B-blockers, Calcium Channel Blockers, and Erythropoiesis-stimulating Agents(ESAs) are some of the major drug class used in the treatment of chronic kidneydisease or its underlying cause.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1713
Global Chronic Kidney DiseaseDrugs Market – Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic hasimpacted the global economy and in turn, the chronic kidney disease drugsmarket. Quarantine, traveling constraints, and social distancing measures arelikely to lead to a steep decline in business and consumer spending until the endof the second quarter of 2020. Moreover, the COVID-19 pandemic has drasticallyaffected clinical trials. Many trials have paused enrollment and researchersare facing multiple challenges associated with setting up remote visits, andperforming laboratory, and other study assessments.
Browse 44 Market Data Tables and39 Figures spread through 206 Pages and in-depth TOC on “Chronic Kidney DiseaseDrugs Market”- Global Forecast to 2027, by Drug Type (ACE Inhibitors,B-Blockers, Calcium Channel Blockers, Loop Diuretics,Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and Others), byRoute of Administration (Oral, Intravenous, and Subcutaneous), by Patient Type(Dialysis and Others), by Distribution Channel (Hospital Pharmacies, RetailPharmacies, and Online Pharmacies), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa),
Furthermore, product approvalsand launches for the treatment of chronic kidney disease are expected to drivethe market growth over the forecast period. For instance, in November 2018,Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (250 mg and 500 mg)tablets indicated for the treatment of hyperphosphatemia in patients withchronic kidney disease on dialysis. Moreover, in June 2019, ReataPharmaceuticals, Inc. received the orphan drug designation from the U.S. Foodand Drug Administration (FDA) for bardoxolone methyl (bardoxolone) indicatedfor the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/chronic-kidney-disease-drugs-market-1713
Key Takeaways of the GlobalChronic Kidney Disease Drugs Market:
The global chronic kidney diseasedrugs market is expected to exhibit a CAGR of 4.0% during the forecast period,owing to growing prevalence of chronic kidney disease and increasing approvals& launches of novel drugs for the treatment of chronic kidney disease. Forinstance, according to Lancet data, prevalence of chronic kidney disease inWestern Europe was estimated at 41,976,625 patients in 2017.
Among drug type,erythropoiesis-stimulating agents (ESAs) segment is estimated to hold a dominantposition in the global chronic kidney disease drugs market in 2020, owing torecent launches of novel products by key players. For instance, For instance,in May 2018, Pfizer Inc. received approval from the U.S. Food and DrugAdministration (FDA) for Retacrit, a biosimilar to Epogen and Procrit (epoetinalfa) by Amgen Inc.
On the basis of route ofadministration, intravenous segment is estimated to hold a dominant position inthe global chronic kidney disease drugs market in 2020 due to increasing regulatoryapproval for intravenous drugs, faster action, and robust pipeline ofintravenous products. For instance, For instance, in February 2017, Amgen, Inc.received approval from the U.S. Food and Drug Administration (FDA) for Parsabiv(etelcalcetide), indicated for the treatment of secondary hyperparathyroidism(sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis
In terms of patient type,dialysis segment is estimated to account for major market share in 2020 due torise in number of patients suffering from end-stage renal disease, growingnumber of dialysis procedures & treatment centers, and increasing researchactivities seeking treatment options for dialysis patients. For instance,According to 2018 annual report of the U.S Renal Data System (USRDS), around750,000 patients per year in the U.S. are affected by kidney failure, which isalso called end stage renal disease (ESRD). Moreover, according to the samesource, around 2 million people worldwide suffer from ESRD every year.
Among distribution channel,hospital pharmacies segment dominated the global chronic kidney disease drugsmarket in 2020, owing to increasing number of patient admission in hospitalsdue to chronic kidney disease, and partnerships & agreements of hospitals withspecialty pharmacies services providers. For instance, according to one of thearticles published in WebMD LLC., in 2018, emergency department visits due toend-stage renal disease (ESRD) increased to an average of 3 per patient peryear in the U.S.
Among regions, North America isestimated to hold largest market share in the global chronic kidney diseasedrugs market in 2020, owing to higher prevalence of chronic kidney disease andend-stage renal disease, and presence of higher number of patients with highblood pressure and diabetes in the region, which are leading causes of chronickidney disease. For instance, according to CDC, high blood pressure anddiabetes are leading causes of chronic kidney disease. Currently, approximately1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure mighthave chronic kidney disease in the U.S.
Key players operating in theglobal chronic kidney disease drugs market include Amgen, Inc., TevaPharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La RocheLtd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., ReataPharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1713
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
